Income Tax Expense (Benefit) of Ambrx Biopharma Cayman, Inc. from 31 Dec 2019 to 30 Jun 2023

Taxonomy & unit: us-gaap: USD
Description: Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary: Ambrx Biopharma Cayman, Inc. quarterly and annual Income Tax Expense (Benefit) in USD history and change rate from 31 Dec 2019 to 30 Jun 2023.
Ambrx Biopharma Cayman, Inc. Income Tax Expense (Benefit) for the quarter ending 30 Jun 2023 was $305,000, a 136% increase year-over-year.
Ambrx Biopharma Cayman, Inc. annual Income Tax Expense (Benefit) for 2022 was $1,937,000, a 193600% increase from 2021.
Ambrx Biopharma Cayman, Inc. annual Income Tax Expense (Benefit) for 2021 was $1,000, unchanged from 2020.
Ambrx Biopharma Cayman, Inc. annual Income Tax Expense (Benefit) for 2020 was $1,000.
Source SEC data: View on sec.gov

Income Tax Expense (Benefit), Quarterly (USD)

Income Tax Expense (Benefit), YoY Quarterly Change (%)

Income Tax Expense (Benefit), Annual (USD)

Income Tax Expense (Benefit), YoY Annual Change (%)

Ambrx Biopharma Cayman, Inc. Quarterly Income Tax Expense (Benefit) (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q2 2023	$305,000	+$176,000	+136%	01 Apr 2023	30 Jun 2023	10-Q	09 Aug 2023	2023	Q2
Q1 2023	$73,000	-$1,514,000	-95%	01 Jan 2023	31 Mar 2023	10-Q	11 May 2023	2023	Q1
Q2 2022	$129,000			01 Apr 2022	30 Jun 2022	10-Q	09 Aug 2023	2023	Q2
Q1 2022	$1,587,000			01 Jan 2022	31 Mar 2022	10-Q	11 May 2023	2023	Q1

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2022	$1,937,000	+$1,936,000	+193600%	01 Jan 2022	31 Dec 2022	10-K	30 Mar 2023	2022	FY
2021	$1,000	$0	0%	01 Jan 2021	31 Dec 2021	10-K	30 Mar 2023	2022	FY
2020	$1,000	+$3,000		01 Jan 2020	31 Dec 2020	20-F	26 Apr 2022	2021	FY
2019	$2,000			01 Jan 2019	31 Dec 2019	20-F	26 Apr 2022	2021	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.